European HIV Clinical Forum: Integrase Inhibitors

Welcome to the European HIV Clinical Forum website!

The European HIV Clinical Forum 2017 was held on 24 October, 2017 in Milan, Italy.

The meeting was a great success with almost 85 attendees visiting the meeting!

The European HIV Clinical Forum focused entirely on Integrase Inhibitors as Integrase Inhibitors are rapidly gaining a central role in the routine care of HIV infected individuals. The HIV Clinical Forum meetings aim at enhancing the clinical skills and research capabilities of HIV healthcare professionals in regard to this unique class of antiretroviral drugs.

Meeting materials such as abstracts, presentations and webcasts will be made available on this website (given that speakers have provided their permission).

We look forward to welcoming you to the next European HIV Clinical Forum on Integrase Inhibitors in 2018, preceding HIV Glasgow in Glasgow, United Kingdom.

On behalf of the European HIV Clinical Forum Program Chairs, we would like to thank ViiV Healthcare for their unrestricted educational grant, as well as Mylan for their generous contribution. We would also like to thank our endorsers for their invaluable support of the meeting and of course a big thank you to all of our participants in making this meeting into a huge success!

We look forward to seeing you again on 27 October 2018, in Glasgow!

Charles Boucher, MD, PhD

Program Chair
Charles Boucher, MD, PhD

Mussini, Cristina 2017

Local Chair
Cristina Mussini, MD

jonathan

Program Chair
Jonathan Schapiro, MD



Program

24 October 2017

8.45h Welcome, Introductions and Goals
Charles Boucher
Erasmus Medical Center, Rotterdam, The Netherlands
Session 1: Basic Principles
9.00h State of the ART: Integrase Inhibitors Resistance
Charles Boucher
Erasmus Medical Center, Rotterdam, The Netherlands
9.30h State of the ART: Integrase Inhibitors (clinical overview)
Jonathan Schapiro
Sheba Medical Center, Israel
10.00h Discussion
10.15h COFFEE BREAK
Session 2: Changing paradigm: Is reducing drug regimen an option?
10.45h What is the virological support for reduced drug regimens?
Anne-Genevieve Marcelin
Pierre and Marie Curie University, Paris, France
11.05h What is the clinical support for reduced drug regimens? David Cooper
University of New South Wales, Australia
11.35h Can we use HIV reservoir assays to predict VF in simplification strategies
Linos Vandekerckhove
Ghent University Hospital, Belgium
11.55h Panel Discussion
12.45h LUNCH
Session 3: Real-life data presentations
13.45h Clinical Case
Cristina Mussini
University of Modena and Reggio Emilia, Italy
Abstract-driven presentations
14.05h Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIV­TR Cohort
D. Yağcı-Çağlayık
14.15h Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.
D. Armenia
14.25h French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network)
A-G. Marcelin
14.35h In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase
O. Delelis
14.45h Changes outside integrase in a patient failing on dolutegravir maintenance monotherapy points to a new resistance mechanism
C. Lungu
14.55h Genetic variability of HIV-2 LTR regions impacts transcriptional activities
Q. Le Hingrat
15.05h Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV‐1‐infected patients with dolutegravir‐based antiretroviral therapy (ART)
R. Palich
15.15h Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48-weeks
A. D’avino
15.25h Clinical Case
Milosz Parczewski
Pomeranian Medical University, Poland
15.45h Discussion
16.15h COFFEE BREAK
Session 4: Changing paradigm: ARV drugs versus immunotherapy
16.30h One pill a day ?: Integration novel delivery systems into routine care
Giovanni Di Perri
University of Turin, Italy
17.00h Prospects of immunotherapy for treatment
Michael Lederman
Case Western Reserve University
17.30h Discussion
17.55h Closure
Networking Dinner

Support

Corporate Support

The 3rd European HIV Forum meeting : Integrase Inhibitors is generously supported by an unrestricted educational grant from ViiV Healthcare.

ViiVHealthcare

Contributor

Global_Mylan_BHBW_Tile_RGB_FC_80

Endorsements

The European HIV Clinical Forum was endorsed by the following organizations. Their support and collaboration play a key role to this meeting’s success and we are proud and honoured to call each and every one of them partners.

Location & Accommodation

Photo GVP 2The European HIV Clinical Forum 2017 was held at the beautiful Grand Visconti Palace.

 

Grand Visconti Palace
Viale Isonzo, 14
20135 Milan, Italy

Tel +39 02 54 03 41 | Fax: +39 02 54 06 95 23

E-mail: info@grandviscontipalace.com

Accommodation
Accommodation for Faculty and grantees has been reserved at the meeting venue for 2 nights on 23-24 October. Not a Faculty member or grantee, but in need of accommodation? Please contact Ms. Charlotte Ballard at charlotte@vironet.com.

Getting to the meeting venue
A short walk from Porta Romana, the hotel is located on the site of one of Milan’s historic industrial buildings.

It is located 150m from the LODI T.I.B.B. Metro stop (line 3 – yellow), 4 km from Milan Central Station, 8km from Milan Linate airport and a couple of kilometres from the junction of the main motorways (A1 and A4).

For more information on how to get to the meeting venue, please click here.

CONTACT US

We're not around right now. Please send us an email and we'll get back to you, asap.

Sending

©2017 Virology Education

Log in with your credentials

or    

Forgot your details?